Fludeoxyglucose

In response to the clinical treatment needs of diseases related to abnormal glucose metabolism such as Alzheimer's disease and diabetic complications, deoxyglucose, as a glucose analog diagnostic and adjuvant therapeutic drug, exerts its effect by specifically interfering with the cellular glycolysis pathway. It is clinically mainly used as a radiolabeled precursor for positron emission tomography (PET) imaging to assist in the early diagnosis of tumors and neurodegenerative diseases, and can also be used as a lead compound for drugs related to diabetic complications. The applicable population covers suspected tumor screening individuals, patients undergoing cognitive dysfunction assessment, and the test population of diseases related to abnormal glucose metabolism.

The global market size related to deoxyglucose was approximately USD 1.27 billion in 2023, and the compound annual growth rate from 2024 to 2030 is expected to reach 8.2%. The growth momentum mainly comes from the increasing penetration rate of early tumor screening and the popularization of nuclear medicine diagnostic technology. In the competitive landscape, the original research product accounts for approximately 62% of the high-end medical market share, and the supply of generic drugs is concentrated in pharmaceutical companies in China and India. With the accelerated construction of nuclear medicine departments in China, the annual growth rate of demand for medical-grade deoxyglucose API is stable at around 11%. It has not been included in the national centralized procurement scope, and the market competition has not yet entered a white-hot stage.

The original research enterprise of deoxyglucose is DuPont Pharmaceuticals of the United States, and the original research trade name is Fludeoxyglucose F 18. Its core compound patent expired globally in 2008, and the preparation process patents in major markets also expired successively in 2016. The main dosage form approved for the original research product is injection, with a conventional specification of 370MBq/10ml, which has been included in the FDA Reference Listed Drug Directory. There is no import approval for the original research preparation in China yet. Up to now, 6 domestic enterprises have obtained CDE API registration numbers (DMF) for deoxyglucose API, among which 3 are in status A, and a total of 11 domestic fludeoxyglucose F 18 injections have been approved for marketing. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for deoxyglucose, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and fully meet the full-process needs of API enterprises in process research, quality research, registration and declaration, etc.